Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mocetinostat - Mirati Therapeutics

Drug Profile

Mocetinostat - Mirati Therapeutics

Alternative Names: 726169-73-9; MG-0103; MGCD-0103; MGCD103; Mocetinostat dihydrobromide

Latest Information Update: 24 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer MedImmune; MethylGene; Mirati Therapeutics; New York University School of Medicine
  • Class Antineoplastics; Benzamides; Pyrimidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Diffuse large B cell lymphoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Malignant melanoma; Rhabdomyosarcoma
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Acute myeloid leukaemia; Hodgkin's disease

Most Recent Events

  • 19 Jun 2020 Mirati Therapeutics completes a phase I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02805660)
  • 09 Jun 2020 Adverse events data from a phase I trial in Melanoma released by Mirati therapeutics
  • 14 May 2020 Phase-I clinical trials in Rhabdomyosarcoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adolescents, In adults) in USA (PO) (NCT04299113)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top